Publicaciones en colaboración con investigadores/as de University College London (28)

2024

  1. Analytical treatment interruption in children living with HIV: position statement from the EPIICAL consortium

    The Lancet HIV, Vol. 11, Núm. 10, pp. e700-e710

  2. Early inflammation as a footprint of increased mortality risk in infants living with HIV from three African countries

    Scientific Reports, Vol. 14, Núm. 1

  3. Effectiveness and Safety of Direct-acting Antivirals for Treatment of Adolescents With HCV/HIV Coinfection: Real-world Data From Europe

    Pediatric Infectious Disease Journal, Vol. 43, Núm. 5, pp. E155-E159

  4. High mortality following early initiation of antiretroviral therapy in infants living with HIV from three African countries

    eClinicalMedicine, Vol. 73

  5. Sustained aviremia despite anti-retroviral therapy non-adherence in male children after in utero HIV transmission

    Nature Medicine, Vol. 30, Núm. 10, pp. 2796-2804

2023

  1. Adeno-associated virus 2 infection in children with non-A–E hepatitis

    Nature, Vol. 617, Núm. 7961, pp. 555-563

  2. Effective early antiretroviral therapy in perinatal-HIV infection reduces subsequent plasma inflammatory profile

    Pediatric Research, Vol. 94, Núm. 5, pp. 1667-1674

  3. Genomic investigations of unexplained acute hepatitis in children

    Nature, Vol. 617, Núm. 7961, pp. 564-573

  4. The hard part we often forget: providing care to children and adolescents with advanced HIV disease

    Journal of the International AIDS Society, Vol. 26, Núm. 3, pp. e26041

2022

  1. Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

    The Lancet HIV, Vol. 9, Núm. 9, pp. e627-e637

2021

  1. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing

    BMC infectious diseases, Vol. 21, Núm. 1, pp. 5

  2. Withholding Primary Pneumocystis Pneumonia Prophylaxis in Virologically Suppressed Patients with Human Immunodeficiency Virus: An Emulation of a Pragmatic Trial in COHERE

    Clinical Infectious Diseases, Vol. 73, Núm. 2, pp. 195-202

2020

  1. Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: A systematic review

    Journal of Antimicrobial Chemotherapy, Vol. 75, Núm. 12, pp. 3433-3457

  2. Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial

    The Lancet HIV, Vol. 7, Núm. 8, pp. e533-e544

  3. The HIV drug optimization agenda: promoting standards for earlier investigation and approvals of antiretroviral drugs for use in adolescents living with HIV

    Journal of the International AIDS Society

2019

  1. Plasma lipid profiles discriminate bacterial from viral infection in febrile children

    Scientific Reports, Vol. 9, Núm. 1

  2. Prioritising the most needed paediatric antiretroviral formulations: the PADO4 list

    The Lancet HIV, Vol. 6, Núm. 9, pp. e623-e631

  3. Reduced Time to Suppression among Neonates with HIV Initiating Antiretroviral Therapy Within 7 Days after Birth

    Journal of Acquired Immune Deficiency Syndromes, Vol. 82, Núm. 5, pp. 483-490

2018

  1. Early and highly suppressive antiretroviral therapy are main factors associated with low viral reservoir in European perinatally HIV-infected children

    Journal of Acquired Immune Deficiency Syndromes

  2. Global temporal changes in the proportion of children with advanced disease at the start of combination antiretroviral therapy in an era of changing criteria for treatment initiation

    Journal of the International AIDS Society, Vol. 21, Núm. 11